Phase 2 N=61 Heart Rate Variability in Response to Metformin Challenge
Fibromyalgia · Mitochondrial Diseases · Movement Disorders
Primary: Heart Rate Variability (Time Domain) — 0.92; 0.83 msec/msec — p=0.77
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Metabolic Syndrome and Fall Risk
Metabolic Syndrome · Autonomic Neuropathy
Primary: Four Square Step Test (FSST) — 11.04; 14.29 seconds
Phase 2 N=405 Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome
Metabolic Syndrome
Primary: Blood Glucose Level — 6.05; 6.43; 4.58; 14.5 mmole/L
N/A N=100 Inflammation and the Metabolic Syndrome in Humans
Metabolic Syndrome X
Primary: The Primary Outcome Measure is Plasma Levels of TNF Alpha. — 507 ng/mL
N/A N=27 Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome
Metabolic Syndrome
Primary: Sarcoplasmic Reticulum Composition — 2.0; 2.2 PC:PE ratio
Phase 4 N=20 Metabolic Abnormalities in HIV-infected Persons
Lipodystrophy · HIV Infection
Primary: Change in Insulin Sensitivity From Baseline to Week 12 Post-treatment With Insulin Sensitizing Agent — -0.25; -0.96 mg/kg lean body mass/min
N/A N=82 Fructose Consumption and Metabolic Dysregulation
Central Obesity · Hypertriglyceridemia
Primary: TG Plasma AUC — 1130; 1220 mmol/l*min — p=0.005
Phase 2 N=35 Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
Metabolic Syndrome X · Overweight · Hypertension
Primary: Insulin Sensitivity — .56; 0.55; 0.66; 0.70 % suppression inf rate 56 pmol/m2/min
N/A N=98 Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation
Mild Cognitive Impairment · Metabolic Syndrome
Primary: MoCA (Montreal Cognitive Assessment) — 28.38; 20.22 score on a scale — p=<0.0001
N/A N=157 Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome
Diabetes Mellitus, Type 2
Primary: Alterations in PKC-zeta mRNA in Vastus Lateralis Skeletal Muscles — 1.76; 3.58; 2.14; 2.22 arbitrary units/ng rRNA — p=.001
N/A N=257 Down Syndrome Metabolic Health Study
Down Syndrome · Trisomy 21
Primary: Non-HDL Cholesterol — 128; 107 mg/dl
Phase 2 N=12 Blood Lipopolysaccharide (LPS) Rifaximin Study
Obese · Insulin Resistance · Metabolic Syndrome
Primary: Circulating LPS — 2.44; 1.86; 13.66; 10.00 EU/mL — p=>0.05
N/A N=177 Diabetes and Lipid Accumulationand Heart Transplant
Diabetes Mellitus · Heart Failure
Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies
Phase 2 N=20 EPI-743 for Metabolism or Mitochondrial Disorders
Mitochondrial Disease · Neurology · Myopathy
Primary: Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) Part I-III, Baseline — 23.9; 20.4 Units on a scale
N/A N=30 Obesity - Inflammation - Metabolic Disease: Effect of Lactobacillus Casei Shirota
Metabolic Syndrome
Primary: Change of Neutrophil Phagocytosis From Baseline to 3 Months — 0.06; 3.48 percentage of monocytes and granulocytes
N/A N=30 Effect of Endoplasmic Reticulum Stress on Metabolic Function
Insulin Resistance · Diabetes · Obesity
Primary: Body Composition — 39; 39; 37; 39 percentage
Phase 2 N=12 Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome
Metabolic Syndrome
Primary: Change in Hepatic Lipogenesis — 5.6 abs percent change fasting lipogenesis
Phase 2 N=28 Metabolic Effects of Betaine Supplementation
Obesity · Dysglycemia
Primary: Fasting and 2 Hour Glucose Levels, Comparing Baseline and 12 Weeks. — -5; 3; 7; -4 mg/dl
N/A N=46 Neurologic Injuries in Adults With Urea Cycle Disorders
Brain Diseases, Metabolic, Inborn · Urea Cycle Disorder · Ornithine Transcarbamylase Deficiency
Primary: Concentration of Glutamine and Myoinositol by MRS — 4.97; 3.66; 3.78; 4.50 mM — p=0.003
Early Phase 1 N=46 Assessment of Renal Function by Multiparametric MRI
Renal Impairment
Primary: T1 Time — 1500 ms
N/A N=24 Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome
HIV Infections · Cardiovascular Disease · Insulin Resistance
Primary: Myocardial Glucose Utilization Rate — 109.6; 106.7; 109.1; 87.2 (nmol glucose/g heart muscle/min
Phase 2 N=60 Metformin in Kidney Disease
Chronic Kidney Disease · Cardiovascular Disease · Metabolic Syndrome
Primary: Change is Leptin to Adiponectin Ratio (LAR) — 2.2; 1.3; 1.3; 1.4 ng/micrograms
N/A N=30 Alleviation Of Metabolic Endotoxemia In Adults With Metabolic Syndrome With Milk Fat Globule Membrane
Metabolic Syndrome · Metabolic Endotoxemia
Primary: Serum Endotoxin — 32.5; 30.6 EU/ml
Phase 2 N=13 High Protein Diet in Patients With Long-chain Fatty Acid Oxidation Disorders
Very Long-chain Acyl-CoA Dehydrogenase Deficiency · Trifunctional Protein Deficiency · Carnitine Palmitoyltransferase 2 Deficiency
Primary: Energy Expenditure — 2045; 2343 kcal
N/A N=73 Metabolic Characteristics of Lean Diabetes in Rural and Semi-urban India and in the United States
Malnutrition; Diabetes · Diabetes
Primary: Endogenous Glucose Production — 0.5; 0.84; 0.6; 0.4 mg/kg/min
Phase 2 N=40 Implications for Treatment of the Metabolic Syndrome
Metabolic Syndrome
Primary: Muscle Microvascular Function — 3.7; 4.0 10^3 mL*min^-1*100ml^-1*mmHg^-1
N/A N=27 Erythrocyte and Adipocyte G6PD Activity Levels in Obesity
Diabetes · Obesity
Primary: Measure Erythrocyte G6PD Levels in Diabetic vs. Non-diabetic Morbidly Obese Patients Undergoing Laparoscopic Gastric Bypass. — 3.12; 0.67; 22; 13 nM/min/mg — p=<0.05
Phase 4 N=24 Metabolic Effects of Antihypertensive Drugs on People With Metabolic Syndrome (The MEAD Study)
Hypertension
Primary: Change in Oral Glucose Tolerance Test (OGTT) Area Under Curve (AUC) After Addition of Trandolapril to Hydrochlorothiazide (HCTZ) Compared With Change in OGTT AUC After…
N/A N=4 Metabolomic Analysis of Hepatic Insulin Resistance
Type 2 Diabetes · Obesity
Primary: Insulin Sensitivity — 8 m value — p=<0.05
N/A N=360 Alcohol Metabolism and Disease Risk in Asians
Healthy
Primary: Peak Number of Alcohol Drinks Consumed in a Day — 3.7; 4.2; 3.4; 3.0 drinks — p=.81